Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
Newsletters
Training
White Papers
Advertising
Contact Us
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Court Sides With Merck in Second Case Over Fosamax

Drug Industry Daily

Nov. 25, 2009 | Vol. 8 No. 230

Court Sides With Merck in Second Case Over Fosamax

A federal court has dismissed allegations that Merck’s osteoporosis drug Fosamax causes jaw bone destruction, two months after declaring a mistrial in a similar suit involving Fosamax liability.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

Lupin Gets FDA Nod to Sell Blood Pressure Drug Almirall Gets EU Approval for Prostate Drug FDA Raises Concerns About Cell Therapeutics’ Cancer Drug Novavax Nixes Flu Vaccine Partnership With Rovi Pharmaceuticals

Home
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.